<DOC>
	<DOCNO>NCT00052637</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure cystoscopy may improve ability detect cancer determine extent disease . PURPOSE : Diagnostic trial compare effectiveness cystoscopy use hexyl 5-aminolevulinate two light source detect carcinoma situ patient bladder cancer .</brief_summary>
	<brief_title>Cystoscopy Hexyl 5-Aminolevulinate Detecting Carcinoma In Situ Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare blue light fluorescent cystoscopy reconstitute hexyl 5-aminolevulinate ( Hexvix® ) v white light cystoscopy detection carcinoma situ ( CIS ) patient bladder cancer . - Compare positive false detection rate histologically confirm non-CIS lesion dysplasia modality patient . - Compare false detection rate histologically confirm CIS lesion modalities patient . - Compare number tumor lesion dysplasia detected modality patient . - Compare management patient evaluation modality . - Determine safety reconstitute hexyl 5-aminolevulinate ( Hexvix® ) patient . OUTLINE : This open-label , multicenter study . Patients undergo bladder catheterization instillation reconstitute hexyl 5-aminolevulinate ( Hexvix® ) . After 60 minute bladder evacuate , patient undergoes cystoscopic examination bladder white light blue light fluorescence . Biopsies take suspicious area see white and/or blue light modality , one normal-appearing area see light modality , papillary lesion resect . Patients follow 7 day procedure . PROJECTED ACCRUAL : A total 420 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Indication cystoscopy suspect confirmed bladder cancer Meets least one follow criterion : Multiple bladder lesion Bladder lesion great 3 cm Bladder tumor least stage T1 Grade 2 3 bladder tumor Recurrent bladder cancer No positive cytology obtain last 4 week No prior G3 tumor one set positive random biopsies No porphyria PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal No gross hematuria Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study No known allergy reconstitute hexyl 5aminolevulinate similar compound No concurrent condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy More 3 month since prior BCG Chemotherapy More 3 month since prior chemotherapy Single prior dose chemotherapy prevention seed resection allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 30 day since prior participation another clinical trial No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage 0 bladder cancer</keyword>
</DOC>